Timmins v. Walmart, Inc.

• Court: District Court, E.D. California
• Decided: June 4, 2025
• Docket: 2:24-cv-02960
• Status: Unknown

Opinion

1 2 3 4 5 UNITED STATES DISTRICT COURT 6 FOR THE EASTERN DISTRICT OF CALIFORNIA 7 8 LACEY TIMMINS, No. 2:24-cv-02960-DJC-JDP 9 Plaintiff, 10 v. ORDER DENYING DEFENDANT’S MOTION TO DISMISS 11 WALMART, INC., 12 Defendant. 13 Plaintiff purchased baby petroleum jelly advertised as hypoallergenic. She later 14 learned the jelly contained fragrance, which she alleges is a known allergen. Plaintiff 15 brought state law claims against Defendant for false advertisement, 16 misrepresentation, and violation of warranty. Defendant moves to dismiss all claims, 17 arguing that Plaintiff’s allegations are insufficient. Principally, Defendant argues that 18 the term hypoallergenic on the front label was sufficiently vague such that Plaintiff 19 should have looked to the back label for additional information, particularly because 20 the Product advertised having a “Fresh Scent.” For the following reasons, the Court 21 GRANTS IN PART and DENIES IN PART Defendant’s Motion to Dismiss (ECF No. 9). 22 BACKGROUND 23 In 2022, Lacey Timmins (“Plaintiff”) purchased Walmart, Inc.’s (“Defendant”) 24 Baby Petroleum Jelly Skin Protectant (“the Product”) to alleviate her son’s eczema and 25 diaper rash. (Compl. ¶¶ 3, 7, ECF No. 1.) Before purchasing the Product, she saw that 26 the front label represented the Product as “hypoallergenic.” (Id. ¶ 8.) Plaintiff alleges 27 that a reasonable consumer understands the term “hypoallergenic” to mean “a 28 1 product [that] is specifically formulated to minimize the risk of allergic reactions and is 2 free from common allergens.” (Id. ¶ 5.) The front label also represented the Product 3 as having a “Fresh Scent.” (Id. at 5.) Plaintiff alleges that the Product’s back label lists 4 “fragrance” as an “inactive ingredient.” (Id. ¶ 23.) Because Plaintiff alleges that 5 “fragrance” is a common allergen, she maintains that Defendant’s representation of 6 “hypoallergenic” was false and misleading. (Id. ¶¶ 24–25.) 7 Plaintiff filed her complaint (“the Complaint”), bringing seven claims on behalf 8 of a putative class: (1) violations of California’s Unfair Competition Law (“UCL”); (2) 9 violations of California’s False Advertising Law (“FAL”); (3) violations of California’s 10 Consumer Legal Remedies Act (“CLRA”); (4) breach of implied warranty; (5) breach of 11 express warranty; (6) unjust enrichment; and (7) fraud by omission/ intentional 12 misrepresentation. (Id. ¶¶ 75–146.) Defendant now moves to dismiss all claims for the 13 reasons analyzed below. (Mot., ECF No. 9.) The matter is fully briefed. On March 6, 14 2025, the Court heard oral argument from the parties on this motion and took the 15 matter under submission. (ECF No. 15.) 16 LEGAL STANDARD 17 A Rule 12(b)(6) motion challenges the sufficiency of a complaint for “failure to 18 state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). “To survive a 19 motion to dismiss [under 12(b)(6)], a complaint must contain sufficient factual matter, 20 accepted as true, to state a claim to relief that is plausible on its face.” Ashcroft v. 21 Iqbal, 556 U.S. 662, 678 (2009) (internal quotations and citation omitted). Plausibility 22 requires “factual content that allows the court to draw the reasonable inference that 23 the defendant is liable for the misconduct alleged.” Id. While “detailed factual 24 allegations” are unnecessary, the complaint must allege more than “[t]hreadbare 25 recitals of the elements of a cause of action, supported by mere conclusory 26 statements.” Id. Conclusory allegations are not to be considered in the plausibility 27 analysis. Id. at 679 (“While legal conclusions can provide the framework of a 28 complaint, they must be supported by factual allegations.”). 1 DISCUSSION 2 I. Sufficiency of Fraud-Based Allegations 3 Defendant contends that Plaintiff fails to sufficiently plead her UCL, FAL, CLRA, 4 unjust enrichment, and fraud by omission/ intentional misrepresentation claims. 5 (Mot. at 8.) Defendant presents three arguments: (1) Plaintiff did not satisfy Federal 6 Rule of Civil Procedure 9(b) because she did not plead with particularity the details of 7 the alleged fraud; (2) Plaintiff did not provide factual allegations showing that 8 “hypoallergenic” is false or misleading; and (3) Plaintiff did not plausibly allege that a 9 reasonable consumer would be misled by the Product’s label. The Court addresses 10 these issues in turn. 11 A. Rule 9(b) 12 Defendant contends that Plaintiff fails to satisfy Rule 9(b). (Mot. at 8.) 13 Allegations based in fraud “must be accompanied by ‘the who, what, when, where, 14 and how’ of the misconduct charged.” Kearns v. Ford Motor Co., 567 F.3d 1120, 1124 15 (9th Cir. 2009) (citation omitted). “To comply with Rule 9(b), allegations of fraud must 16 be specific enough to give defendants notice of the particular misconduct which is 17 alleged to constitute the fraud charged so that they can defend against the charge 18 and not just deny that they have done anything wrong.” Swartz v. KPMG LLP, 476 19 F.3d 756, 764 (9th Cir. 2007) (cleaned up). 20 Plaintiff sufficiently alleges the “who, what, when, where, and how” of the 21 misconduct charged. See Kearns, 567 F.3d at 1124 (citation omitted). The “who” is 22 Defendant. (Compl. ¶ 3.) The “what” is the Product, specifically the front label’s 23 representation that it is “hypoallergenic.” (Id. ¶¶ 3–4.) The “where” is Defendant’s 24 stores where the Product is sold. (Id. ¶ 65.) The “when” is sometime in 2022 or, as 25 Plaintiff defines the class, every transaction since October 28, 2020. (Id. ¶¶ 7, 65.) 26 The “how” is that the Product contains fragrance, which is a common allergen, and 27 therefore the Product is allegedly not “hypoallergenic” as advertised. (Id. ¶ 4.) 28 Defendant argues that Plaintiff has not sufficiently pled the “when,” “what,” or 1 “how” of the alleged fraud. (Mot. at 8–9.) Regarding the “when,” Defendant contends 2 Plaintiff’s allegation of purchasing the Product “in 2022” is not specific enough. (Id. 3 (citing Compl. ¶ 7).) To support its argument, Defendant relies on Buckley v. BMW 4 North America, where the district court held that plaintiff’s allegation of “the middle of 5 September” was not precise enough because their allegations concerned 6 representations made by the defendant’s sales agents. Buckley v. BMW N. Am., No. 7 CV 19-1255-MWF-SS, 2020 WL 3802905, at *2 (C.D. Cal. Mar. 9, 2020). The Buckley 8 court held that, to prepare an adequate answer, the defendant needed more 9 information to determine the identity of the sale agents and therefore be on notice of 10 the misconduct alleged. Id. at *11. However, Buckley is distinct from the present 11 action because, while the defendant there needed more precise information to 12 identify the transaction where the alleged fraud occurred, Defendant here has not 13 shown that it needs further details of the charged misconduct. Defendant fails to 14 explain how it is unable to answer the Complaint without more specificity as to when 15 Plaintiff purchased the Product in 2022. As Plaintiff alleges, and the Court accepts as 16 true for purposes of this motion, the Product’s packaging has been consistent for the 17 last four years, which means the label has stayed the same since October 28, 2020. 18 (Compl. ¶ 34.) 19 Regarding the “what” and “how” of the fraud, Defendant argues Plaintiff must 20 allege what she believed “hypoallergenic” to mean, as well as how she came to learn 21 that the Product was not free of common allergens. (Mot. at 9.) Defendant fails to 22 explain why Plaintiff’s knowledge of the term “hypoallergenic” is necessary to put it 23 on notice of the alleged fraud.1 Likewise, Defendant fails to explain why it needs to 24 know when Plaintiff learned that the Product was not free of common allergens. 25 Defendant is on notice of the charged misconduct without such allegations. 26 1 Similarly, Defendant’s argument concerning Plaintiff’s litigation in the related case is also irrelevant to 27 the analysis of her claims here, especially because Plaintiff brought her other action for a product she purchased in 2023—a year after she purchased the Product. (See Reply at 6, ECF No. 12; Lacey Timmins 28 v. Unilever United States, Inc., 2:24-cv-03017-DJC-JDP (E.D. Cal.).) 1 Accordingly, Plaintiff’s allegations comply with Rule 9(b) because they give 2 Defendant “notice of the particular misconduct which is alleged to constitute the 3 fraud charged” so that it can defend against the charge. See Swartz, 476 F.3d at 764. 4 B. Whether the Label Is False or Misleading 5 Defendant argues that Plaintiff fails to allege sufficient facts showing that 6 “hypoallergenic” is false or misleading. (Mot. at 9.) Defendant relies on Aloudi v. 7 Intramedic Research Group, LLC, where the Ninth Circuit held that the plaintiff failed 8 to allege sufficient facts to support a claim that a product’s representation of being 9 “clinically proven” to “provide a significant reduction in actual body mass index” was 10 false. 729 F. App’x 514, 515–16 (9th Cir. 2017). In the Aloudi complaint, plaintiff 11 alleged that rapid weight loss was “medically impossible without drastic medical 12 intervention or serious illness,” cited a study concerning a different product, and pled 13 that he did not lose weight after taking the product as directed. Id. at 516–17. The 14 Ninth Circuit held that these factual allegations did not support a claim that the 15 specific representation of the product was false. Id. at 517. 16 Aloudi is distinguishable because Plaintiff here has alleged specific facts about 17 why the representation of the Product being “hypoallergenic” was false and 18 misleading. Plaintiff defines “hypoallergenic” as “a Product [that] is specifically 19 formulated to minimize the risk of allergic reactions and is free from common 20 allergens.” (Compl. ¶ 5). She includes dictionary definitions that “hypoallergenic” 21 means “having little likelihood of causing an allergic reaction” or “designed to reduce 22 or minimize the possibility of an allergic response.” (Id. ¶ 21.) Plaintiff further alleges 23 that the front label representation of “hypoallergenic” was incorrect because the 24 Product contained the ingredient “fragrance,” which is ”one of the most common 25 allergens and skin irritants, and a leading cause of allergic contact dermatitis 26 according to the American Academy of Dermatology (‘AAD’). The AAD estimates 27 about 2.5 million Americans have fragrance allergies.” (Id. ¶¶ 24–25.) Plaintiff pleads 28 that fragrance can cause allergic reactions, including on a cellular level. (Id. ¶¶ 27– 1 28.) Taken together, the Court holds that these factual allegations sufficiently support 2 Plaintiff’s claim that the Product was false or misleading. 3 C. Reasonable Consumer 4 Defendant argues that Plaintiff does not plausibly allege that a reasonable 5 consumer would be misled by the Product’s label. (Mot. at 11.) “[C]laims under the 6 UCL, FAL, and CLRA are governed by the ‘reasonable consumer’ standard,” which 7 requires a plaintiff to “show that members of the public are likely to be deceived.” 8 McGinity v. Procter & Gamble Co., 69 F.4th 1093, 1097 (9th Cir. 2023) (internal 9 quotations and citations omitted). Courts begin this analysis by focusing on the front 10 label, and they may consider the back label of a product only if the front label creates 11 ambiguity such that “reasonable consumers would necessarily require more 12 information before they could reasonably conclude that the front label was making a 13 specific representation.” Whiteside v. Kimberly Clark Corp., 108 F.4th 771, 780 (9th 14 Cir. 2024) (internal quotations and citations omitted). “California courts . . . have 15 recognized that whether a business practice is deceptive will usually be a question of 16 fact not appropriate for” a motion to dismiss. Williams v. Gerber Prods. Co., 552 F.3d 17 934, 938 (9th Cir. 2008). 18 The Court is guided by the Ninth Circuit’s recent decision in Souter v. Edgewell 19 Personal Care Co., where the plaintiff purchased Wet Ones Hand Wipes advertised as 20 “hypoallergenic” on the label.2 No. 22-55898, 2023 WL 5011747, at *1 (9th Cir. Aug. 21 7, 2023). Relying on a dictionary definition, the plaintiff alleged in the complaint that 22 a reasonable consumer would believe “hypoallergenic” meant the Hand Wipes were 23 “designed to reduce or minimize the possibility of an allergic response, as by 24 containing relatively few or no potentially irritating substances.” Id. at *2. The district 25 court proposed its own definition of “hypoallergenic” and dismissed the plaintiff’s 26

27 2 Defendant points out that Souter is unpublished and therefore not precedential. (Reply at 8.) Because Souter was decided after 2006, the Court relies on it as persuasive authority. Fed. R. App. P. 28 32.1; see also Ninth Circuit Rule 36-3. 1 claims, holding that she failed to allege “that a reasonable consumer would assume 2 that the Hand Wipes have ‘no potential allergens.’” Id. at *3. The Ninth Circuit 3 reversed, holding, “At the motion to dismiss stage, it was improper for the district 4 court to select between competing plausible interpretations of an ambiguous term.” 5 Id. 6 Defendant argues that Souter is inapposite because Plaintiff does not plead a 7 plausible definition of “hypoallergenic.”3 (Mot. at 12.) Plaintiff defines 8 “hypoallergenic” as “a Product [that] is specifically formulated to minimize the risk of 9 allergic reactions and is free from common allergens.” (Compl. ¶ 5). This definition is 10 substantially similar to the definition the plaintiff offered in Souter. See 2023 WL 11 5011747, at *2 (defining the term as meaning the product was “designed to reduce 12 or minimize the possibility of an allergic response, as by containing relatively few or 13 no potentially irritating substances”). Plaintiff also bases her interpretation on 14 dictionary definitions that define “hypoallergenic” as “having little likelihood of 15 causing an allergic reaction” or “designed to reduce or minimize the possibility of an 16 allergic response.” (Compl. ¶ 21.) As such, the Court holds that Plaintiff’s definition is 17 plausible. Even if Defendant or the Court could construct a competing plausible 18 definition, it would be improper at this stage for the Court to “select between 19 competing plausible interpretations of an ambiguous term.” See Souter, 2023 WL 20 5011747 at *3. Accordingly, Plaintiff plausibly states that reasonable consumers 21 would interpret the Product’s representation of “hypoallergenic” as meaning the 22 Product is “specifically formulated to minimize the risk of allergic reactions and is free 23 from common allergens.” (Compl. ¶ 5.) Because the Product allegedly contains a 24 common allergen, Plaintiff plausibly shows that “members of the public are likely to 25 3 Defendant also argues that Souter is inapposite because Plaintiff has failed to identify an ingredient 26 more specific than “fragrance.” (Mot. at 12–13.) But Plaintiff is unable to provide any more detailed information because the Product’s back label simply lists the ingredient as “fragrance.” (See Compl. at 27 6.) Defendant is, in effect, demanding information that it does not provide to the public, and then arguing that failure to furnish such information is cause for dismissal. Defendant also does not explain 28 why a more particular allegation is necessary for Souter to be on point. 1 be deceived” by the Product’s claim of being “hypoallergenic.” See McGinity, 69 2 F.4th at 1097 (internal quotations and citation omitted); Compl. ¶ 4. 3 Defendant contends that the front label’s inclusion of the term “Fresh Scent” 4 creates ambiguity such that the Court must consider the back label’s inclusion of 5 “fragrance” as an “inactive ingredient. (Mot. at 11–12 (citing McGinity, 69 F.4th at 6 1099).) A court may only consider the back label if a reasonable consumer would 7 necessarily require more information before they could reasonably conclude that the 8 front label was making a specific representation. See Whiteside, 108 F.4th at 780. 9 Defendant argues that a reasonable consumer would interpret “Fresh Scent” as 10 meaning the Product contained fragrance, which would create ambiguity with the 11 reasonable consumer’s understanding of “hypoallergenic.” (Id. at 12.) Although in 12 the Court’s view this is a close question, for purposes of this motion, the Court 13 accepts that the Product’s representation of “hypoallergenic” is unambiguous: it tells 14 the consumer that the Product is free of common allergens. The term “Fresh Scent” 15 does not, as a matter of law, create ambiguity regarding this representation. As 16 Plaintiff states, a reasonable consumer might interpret “Fresh Scent” to mean the 17 Product does not have an “off-putting smell” or “smells pleasant.” (Opp’n at 15, ECF 18 No. 11.) Moreover, the reasonable consumer standard “is evaluated from the 19 perspective of the ordinary consumer within the larger population, who is not 20 typically exceptionally acute or sophisticated or wary and suspicious of advertising 21 claims.” Souter, 2023 WL 5011747, at *1 (cleaned up). From this vantage point, the 22 inclusion of ”Fresh Scent” does not change the finding that a reasonable consumer 23 would believe that “hypoallergenic” was making a specific representation about the 24 Product. Accordingly, because reasonable consumers would not require more 25 information before concluding the front label was making a specific representation, 26 the Court cannot consider the back label. See Whiteside, 108 F.4th at 780. 27 Because the Court rejects each of Defendant’s arguments regarding Plaintiff’s 28 fraud-based allegations, the Court denies Defendant’s motion as to Plaintiff’s UCL, 1 FAL, CLRA, unjust enrichment, and fraud by omission/ intentional misrepresentation 2 claims. 3 II. Express and Implied Warranty 4 Defendant asks the Court to dismiss Plaintiff’s express and implied warranty 5 claims for failure to comply with California law. (Mot. at 13.) California Commercial 6 Code Section 2607 provides that a plaintiff must “within a reasonable time after he or 7 she discovers or should have discovered any breach, notify the seller of breach or be 8 barred from any remedy.” Cal. Com. Code § 2607(3)(A). “This notice requirement is 9 designed to allow the seller the opportunity to repair the defective item, reduce 10 damages, avoid defective products in the future, and negotiate settlements.” 11 Cardinal Health 301, Inc. v. Tyco Elecs. Corp., 169 Cal. App. 4th 116, 135 (2008). 12 California Commercial Code Section 1205 states, “Whether a time for taking an action 13 required by this code is reasonable depends on the nature, purpose, and 14 circumstances of the action.” Cal. Comm. Code § 1205(a). “The question whether 15 notice was properly given must be determined from the particular circumstances and, 16 where but one inference can be drawn from undisputed facts, the issue may be 17 determined as a matter of law.” Cardinal Health, 169 Cal. App. 4th at 136–37 18 (cleaned up). 19 Plaintiff sent Defendant a demand letter on September 30, 2024. (Mot. at 13 20 (citing Michael Healy Decl. ¶ 3, ECF No. 9-2).) Plaintiff does not specify when in 2022 21 she purchased the Product. (Compl. ¶ 7). More importantly, she does not allege 22 when she learned about the breach (i.e. the Product containing fragrance). Without 23 further allegations regarding the nature and circumstances of the time between 24 discovery of breach and Plaintiff’s notice, the Court is unable to conclude whether it is 25 plausible that Plaintiff provided notice within a reasonable time as required by 26 California law. 27 Because Plaintiff fails to allege the circumstances that allow the Court to 28 determine if notice was reasonable as a matter of law, the Court grants Defendant’s 1 motion as to Plaintiff’s express warranty and implied warranty claims. Leave to amend 2 is granted because Plaintiff could save these claims by amendment. See Intri-Plex 3 Techs., Inc. v. Crest Group, Inc., 499 F.3d 1048, 1056 (9th Cir. 2007). 4 III. Equitable Remedies 5 Defendant opposes two forms of relief that Plaintiff seeks in her Prayer for 6 Relief. (See Compl. at 21–22.) First, Defendant contends that Plaintiff cannot seek 7 restitution. (Mot. at 14–15.) Defendant cites several cases, none of which support 8 dismissing a claim for restitution upon a motion to dismiss. See id. (citing Kenney v. 9 Fruit of the Earth, Inc., No. 23-55583, 2024 WL 4578981, at *1 (9th Cir. Oct. 25, 2024) 10 (affirming the district court’s order granting summary judgment on plaintiff’s 11 equitable claims in favor of defendants because monetary damages were an 12 adequate legal remedy); Leslie v. Gen. Motors LLC, No. 1:24-CV-00915-JLT-SAB, 13 2024 WL 4190072, at *7 (E.D. Cal. Sept. 13, 2024) (holding that plaintiff did not have 14 standing to seek injunctive relief); Watson v. Crumbl LLC, 736 F. Supp. 3d 827, 839 15 (E.D. Cal. 2024) (same); Guzman v. Graham Packaging Co., L.P., No. 2:24-CV-00498- 16 TLN-AC, 2024 WL 4289581, at *6 (E.D. Cal. Sept. 25, 2024) (dismissing UCL claim 17 where plaintiff did not allege she lacked an adequate remedy at law)). To seek 18 equitable remedies at the pleading stage, a plaintiff need only allege that they might 19 lack an adequate remedy at law. See Valiente v. Simpson Imports, Ltd., 717 F. Supp. 20 3d 888, 906–07 (N.D. Cal. 2024) (collecting cases). Plaintiff satisfies this requirement 21 by alleging that available legal remedies “are inadequate because they are not 22 equally prompt, certain, or efficient as equitable relief.” (Compl. ¶ 84.) 23 Second, Defendant argues that Plaintiff does not have standing to seek 24 injunctive relief. (See Mot. at 15–16.) The Ninth Circuit held that a plaintiff has 25 standing to seek an injunction against a product’s misleading representation where 26 “the plaintiff faces an actual and imminent threat of future injury.” Davidson v. 27 Kimberly-Clark Corp., 889 F.3d 956, 968 (9th Cir. 2018). The court explained, “In 28 some cases, the threat of future harm may be the consumer’s plausible allegations 1 that she will be unable to rely on the product’s advertising or labeling in the future, 2 and so will not purchase the product although she would like to. . . . In other cases, 3 the threat of future harm may be the consumer’s plausible allegations that she might 4 purchase the product in the future, despite the fact it was once marred by false 5 advertising or labeling, as she may reasonably, but incorrectly, assume the product 6 was improved.” Id. at 969–70. 7 Here, Plaintiff alleges that it is “possible” that she “would purchase the Product 8 in the future if the representations were truthful” because she “continues to buy 9 similar products in the marketplace.” (Compl. ¶ 47.) Plaintiff also alleges that she 10 “remains interested in purchasing similar healing jelly products that are truly 11 hypoallergenic. However, she cannot know for certain whether the false labeling of 12 the Product has been or will be corrected.” (Id. ¶ 10.) These allegations not only 13 satisfy the requirement outlined in Davidson but, in fact, are the precise examples the 14 court provided that would establish standing for injunctive relief. See Davidson, 889 15 F.3d at 969–70. 16 Accordingly, the Court denies Defendant’s motion as to Plaintiff’s request for 17 equitable remedies. 18 IV. Nationwide Class 19 Finally, Defendant asks the Court to limit the putative class to claims under 20 California law on behalf of other California consumers (i.e. exclude consumers 21 outside California). (Mot. at 6–8.) To determine the scope of the class in this action, 22 the Court would need to conduct a case-specific choice-of-law analysis that it cannot 23 undertake at this time because it does not know the “facts and circumstances” of the 24 proposed class. See Mazza v. Am. Honda Motor Co., 666 F.3d 581, 589–94 (9th Cir. 25 2012), overruled on other grounds by Olean Wholesale Grocery Coop., Inc. v. Bumble 26 Bee Foods LLC, 31 F.4th 651 (9th Cir. 2022) (whether out-of-state class members 27 must pursue claims under their own states’ consumer protection statutes instead of 28 California’s depends on a multi-stage choice-of-law analysis specific to the “facts and 1 | circumstances” of the particular case). This determination is proper upon a motion 2 | for class certification, not a motion to dismiss, and thus it would be premature for the 3 || Court to dismiss class claims at this stage. Accord Watson, 736 F. Supp. 3d at 849. 4 | Accordingly, the Court denies Defendant's motion as to Plaintiff's nationwide class 5 | claims. 6 CONCLUSION 7 For the reasons set forth above, IT IS HEREBY ORDERED that Defendant's 8 | Motion to Dismiss (ECF No. 9) is GRANTED IN PART and DENIED IN PART. 9 | Specifically, the Court dismisses with leave to amend Plaintiff's express warranty and 10 | implied warranty claims. 11 If Plaintiff elects to file an Amended Complaint, she must do so within twenty- 12 | one (21) days of this Order. Defendant shall file its response to the Amended 13 | Complaint within twenty-one (21) days after Plaintiff files an Amended Complaint or 14 | after the time to amend has passed, whichever occurs first. 15 16 IT 1S SO ORDERED. 17 | Dated: _ June 4, 2025 “Daal J CoO □□□□ Hon. Daniel alabretta 18 UNITED STATES DISTRICT JUDGE 19 20 21 22 23 24 25 26 27 28 12